Trialbee has secured a majority investment from Varsity Healthcare Partners, while Industrifonden retains a minority stake, aimed at enhancing the company's global patient recruitment capabilities and scaling its operations.

Target Information

Trialbee, a global frontrunner in technology-driven patient recruitment for clinical trials, has recently finalized a majority investment by Varsity Healthcare Partners. As part of this transaction, Industrifonden, which has been a supporter of Trialbee since its inception, is selling the majority of its shares while retaining a minority stake in the company. This strategic partnership aims to enhance Trialbee's Honey Platform™ and expand its global delivery capabilities.

Through this investment, Trialbee intends to solidify its position as a leader in global patient recruitment, thereby providing critical support to biopharma sponsors engaged in complex clinical development programs. Under the leadership of CEO Matt Walz, the company has demonstrated robust growth and innovation, significantly expanding its platform's capabilities over the past year.

Industry Overview

The clinical trial recruitment industry is experiencing transformative growth, driven by an increasing number of clinical studies and the gradual complexity of these trials. In many countries, the surge in biopharma research is